Thyroid Cancer (TC)
Thyroid Cancer includes papillary, follicular, and other subtypes with distinct genomic features. Molecular alterations influence diagnosis and targeted therapy use.
Biomarkers used in this indication
Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.
Defined explicitly for Thyroid Cancer (TC) in FDA labeling.
No indication-specific biomarkers are currently mapped for this indication.
Defined at the solid tumor level and applicable to Thyroid Cancer (TC) and other solid tumor cancers.
Therapies with biomarker-defined approvals
Each therapy below has at least one FDA companion diagnostic approval tied to Thyroid Cancer (TC). Select a therapy to view the specific approval and eligible tests.
deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High)
deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High); TMB (TMB ≥ 10 mutations per megabase)
RET (fusions)
NTRK1, NTRK2 and NTRK3 (fusions)
NTRK1, NTRK2 and NTRK3 (fusions)